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ABSTRACT 
Background & Aims: Colorectal cancers (CRC) with microsatellite instability (MSI) 
and a mismatch repair (MMR) deficit without hypermethylation of the MLH1 promoter 
are likely to be caused by Lynch syndrome. Some patients with these cancers have not 
been found to have pathogenic germline mutations, and are considered to have Lynch-
like syndrome (LLS). The aim of this study was to determine the risk of cancer in 
families of patients with LLS. 
 
Methods: We studied a population-based cohort of 1705 consecutive patients, 
performing MSI tests and immunohistochemical analyses of MMR proteins. Patients 
were diagnosed with Lynch syndrome when they were found to have pathogenic 
germline mutations. Patients with MSI and loss of MSH2 and/or MSH6 expression, 
isolated loss of PMS2, or loss of MLH1 without MLH1 promoter hypermethylation and 
no pathogenic mutation were considered to have LLS. The clinical characteristics of 
patients and the age- and sex-adjusted standardized incidence ratios (SIR) of cancer in 
families were compared between groups.  
 
Results: The incidence of CRC was significantly lower in families of LLS patients than 
families with confirmed Lynch syndrome cases (SIR for Lynch syndrome=6.04; 95% 
confidence interval [CI], 3.58−9.54 and SIR for LLS=2.12; 95% CI, 1.16−3.56; P<.001). 
However, the incidence of CRC was higher in families of patients with LLS than in 
families with sporadic CRC (SIR for sporadic CRC=0.48; 95% CI, 0.27−0.79; P<.001).  
 
Conclusions: The risk of cancer in families with LLS is lower that of families with 
Lynch syndrome, but higher than that of families with sporadic CRC. These results 
confirm the need for special screening and surveillance strategies for these patients 
and their relatives. 
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INTRODUCTION 
 
Lynch Syndrome (LS) is the most common inherited colon cancer susceptibility 
syndrome caused by germline mutations in one of several DNA mismatch repair (MMR) 
genes, mainly MLH1 and MSH2, but also MSH6 and PMS2.1-3 Patients with LS have an 
increased risk of colorectal cancer (CRC), endometrial cancer, and several other 
cancers, including ovarian, upper urinary tract, gastric, small bowel, biliary/pancreatic, 
skin, and brain cancers. The molecular signature of LS is microsatellite instability (MSI), 
which is found in more than 95% of LS-associated CRCs.4 However, MSI is also 
present in up to 15% of sporadic CRCs, due to hypermethylation of the promoter region 
of MLH1 in tumor cells. Immunohistochemical (IHC) studies of MMR proteins have 
been shown to be equivalent to MSI in detecting MMR-defective CRC.5 CRC with MSI 
and a lack of staining of MSH2, MSH6, or MLH1 without promoter hypermethylation is 
a strong indicator of MSH2, MSH6, or MLH1 germline mutations.6 However, some of 
these CRC cases do not have pathogenic mutations in MMR genes. These cases are 
suspected to be non-sporadic because no mechanism of inactivation is known for 
these genes other than germline mutations in the context of LS. These patients are 
considered to have “probably non-sporadic” colorectal cancer or “Lynch-like” syndrome 
(LLS), and decisions about their management are not simple because of unconfirmed 
suspicions of hereditary cancer. These patients must be distinguished from familial 
CRC type X, where tumors do not show MMR deficiency. No studies have 
characterized these CRC patients, and the risk of cancer in this group of families is not 
known. Therefore, the surveillance strategy for these patients and their relatives is 
unclear.  
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We analyzed the clinical and familial characteristics of patients diagnosed with LLS, LS, 
or sporadic CRC. The main aim of this study was to determine the risk of cancer in 
families of patients with LLS. 
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METHODS 
 
Patients and data collection 
The present study was a population-based observational cohort study including 1,705 
patients with CRC from two nationwide multicenter studies, EPICOLON I and 
EPICOLON II. EPICOLON I included consecutive patients with a new diagnosis of 
CRC between November 2000 and October 2001 with the main goal of estimating the 
incidence of LS in Spain.7 EPICOLON II also included consecutive newly diagnosed 
CRC patients between March 2006 and December 2007 with the aim of investigating 
different aspects related to the diagnosis of hereditary CRC.8 All of the patients 
provided written informed consent. Both studies were approved by the institutional 
review boards of the participating hospitals. 
Patients were divided into three groups based on genetic data: 1) LS group, patients 
with a confirmed pathogenic mutation in MLH1, MSH2, MSH6, or PMS2; 2) LLS group, 
patients with MSI and loss of MSH2/MSH6 expression, isolated loss of PMS2, or loss 
of expression of MLH1 without MLH1 promoter hypermethylation in which no germline 
mutation was found; and 3)  sporadic group, patients with CRC and MSS tumors 
showing normal expression of MMR genes or a loss of MLH1 expression with MLH1 
promoter hypermethylation. 
Demographic, clinical, and pathology data were collected at the time of diagnosis. 
Cancer pedigrees were built at diagnosis for CRC cases in the EPICOLON I and II 
studies. The pedigrees were traced backward and laterally as far as possible. This 
information was verified by reviewing medical records when available. Standardized 
incidence ratios (SIR) for cancer were calculated as the ratio of the observed to 
expected number of cases diagnosed in the families at the time of inclusion in the 
EPICOLON I or II cohorts. In order to avoid recall bias, only cancer cases found in first-
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degree relatives were included in the calculation of SIR. We considered tumors in the 
endometrium, ovaries, upper urinary tract, stomach, small intestine, and hepatobiliary 
system as non-colorectal LS-related cancers (LSRC). The index case was excluded for 
the analysis of family history at the time of diagnosis. Calculation of the SIR was only 
possible in families with complete pedigrees and information about the ages of all 
family members, including relatives without cancer.  
In 2011, the pedigrees were updated by asking patients and/or relatives about new 
cancer cases after diagnosis of the index case. We include the index case for this 
analysis, and the appearance of metachronous CRC or a new case of LSRC in the 
index case was considered a new case in the family.  
 
Microsatellite instability, immunohistochemical staining, and detection of 
germline mutations 
MSI analysis was performed in all patients. We ascertained MSI status using BAT26 
and NR24 quasimonomorphic markers as described previously.9 MSI was present 
when one of the two markers was unstable. IHC analysis of the four mismatch repair 
proteins MLH1, MSH2, MSH6, and PMS2 in tumor tissue was performed in all patients 
using tissue microarrays (TMAs) as described previously.10 In patients with a loss of 
MLH1, methylation of MLH1 and BRAF mutation status were analyzed. MLH1 
methylation analysis was performed using methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA) according to the manufacturer´s protocol 
using the SALSA MS-MLPA kit ME011 Mismatch Repair Genes (MRC-Holland, 
Amsterdam, the Netherlands).11 The V600E BRAF mutation was detected using 
specific TaqMan probes in real-time PCR (ABI PRISM 7500, Applied Biosystems, 
Foster City, CA, USA) and allelic discrimination software as described previously.12  
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Germline mutation analysis was performed in accordance with the results of the IHC 
analysis as described previously.10 Patients with loss of MSH2 expression with no 
detected mutation were analyzed for EPCAM rearrangements using MLPA (MRC-
Holland, Amsterdam, the Netherlands) according to the manufacturer's recommended 
protocol. DNA sequencing was performed to characterize the deletion breakpoints.13 
Large rearrangements (deletions and insertions) were tested using MLPA (MRC-
Holland) according to the manufacturer´s protocol. The genetic analysis results were 
interpreted based on the ACMG Recommendations for Standards for Interpretation of 
Sequence Variations (2000) and the InSIGHT database.14  
 
Statistical analysis 
Continuous variables are reported as mean ± standard deviation (SD) or medians and 
25th and 75th percentiles for non-normally distributed data. Categorical variables are 
reported as frequencies or percentages. Significant differences between groups were 
analyzed using the chi-square test for categorical data and the non-parametric Mann-
Whitney U test for quantitative data.  
The SIR of each cancer was calculated as the ratio of the observed to expected 
number of cases among relatives. Person-years were calculated from 20 years of age 
until the earliest cancer diagnosis or death. The expected number of cases was 
calculated as the sum of the products of the number of person-years for each 5-year 
age/sex group and the corresponding age/sex-specific incidence rates in Spanish 
regional registers.15 The confidence limits were based on the Byar's approximation of 
the exact Poisson distribution, which is accurate even with small numbers.16 All 
reported p-values are two-sided, and p < 0.05 was considered significant. All 
calculations were performed using the SPSS 19.0 software. 
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RESULTS  
 
A total of 1,705 patients with CRC were included in the study. The median age was 71 
years (range: 27-101 years) and 59% of patients were male. Sixteen patients were 
excluded because of discrepancies between the IHC and MSI analyses; no mutation 
was found in these patients. Therefore, data from 1,689 patients were analyzed. 
Tumors from all patients were analyzed. A total of 135 patients (8%) exhibited in 
their tumors MSI and loss of expression of any of the MMR proteins. In 104 patients 
(6.1%), loss of MLH1 expression was found in IHC analysis. Of these patients, 25 
(1.4%) did not exhibit hypermethylation of the promoter region. We also used BRAF 
mutation as a sporadic CRC marker in these 25 cases, but no case of BRAF mutation 
indicating sporadic origin was found. Loss of MSH2 expression was seen in the IHC 
analysis of 22 patients (1.3%). Three patients (0.2%) had an isolated loss of MSH2 
expression, and 19 (1.1%) had a combined loss of MSH2 and MSH6. Isolated loss of 
MSH6 was found in 6 (0.3%) patients. Finally, an isolated loss of PMS2 was found in 3 
patients (0.2%).  
A germline pathogenic mutation in any of the MMR genes was found in 16 patients 
(0.9%) and considered to have LS. Three of these patients exhibited MSI with non-
valuable expression of MMR proteins in IHC analysis. Four of the LS patients were 
found to have a pathogenic mutation in MLH1, eight in MSH2, three in MSH6, and one 
in PMS2. All of these patients exhibited MSI. No case was found with deletions in 
EPCAM. Variants of uncertain significance were found in five patients (Supplementary 
Table 1). Forty-three patients (2.5%) exhibited MSI and loss of MSH2/MSH6, PMS2, or 
MLH1 expression without promoter hypermethylation, but no pathogenic germline 
mutation was found. These patients were considered to have LLS. Among the LLS 
patients, 21 were found to have a loss of MLH1 protein expression, and 22 loss of 
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MSH2, MSH6, or PMS2 expression (14 with loss of MSH2 and MSH6, 6 with isolated 
loss of MSH6, and 2 with isolated loss of PMS2). Finally, 1,630 patients (96%) were 
considered to have sporadic CRC.  
 
Demographic, clinical, and pathological characteristics of patients with LLS 
The characteristics of the LLS group (n=43) were compared to the LS (n=16) and 
sporadic CRC (n=1630) groups (Table 1). Fewer LLS patients fulfilled the revised 
Bethesda guidelines than LS patients, and LLS patients less often had a personal 
history of non-colorectal LSRC compared to LS patients. No differences were found in 
the presence of metachronous CRC, median age at diagnosis of CRC, sex and tumor 
characteristics, such as location or TNM classification. When we compared LLS 
patients to sporadic CRC patients, patients with LLS were younger at diagnosis, 
predominantly female, and more frequently fulfilled the revised Bethesda guidelines. 
Personal history of non-colorectal LSRC was more frequent in patients with LLS 
without differences in the presence of metachronous or synchronous CRC (Table 1). 
 
Familial cancer risk 
A total of 13 families with LS and 25 families with LLS had complete pedigrees 
including the ages of relatives without cancer. A random sample of 115 families with 
sporadic CRC was used for a comparison. A total of 1,102 first-degree relatives were 
included: 80 from LS families, 177 from LLS families, and 845 from sporadic CRC 
families. The mean number of first-degree relatives was 6.1 for LS families, 7.0 in LLS 
families, and 7.3 in sporadic CRC families.  
In LS families we identified 18 cases of CRC and six cases of non-colorectal LSRC. 
Only in 4 (30.7%) families there was no cancer case other than the index case. In LLS 
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families, we found 14 cases of CRC and eight cases of non-colorectal LSRC. In 12 out 
of 25 families (48%), no case of cancer was found other than the index case. The 
characteristics of patients and distribution of cancer cases in LLS families are provided 
in Table 2. Finally, in sporadic CRC families, 15 first-degree relatives had CRC and 27 
had non-colorectal LSRC. In 85 (79.9%) families no cancer cases were identified other 
than the index case. 
The SIR of CRC and non-colorectal LSRC are found in Table 3. The incidence of CRC 
was significantly lower in LLS families compared to confirmed LS families (SIR in LS: 
6.04, 95% CI 3.58-9.54; SIR in LLS: 2.12, 95% CI 1.16-3.56; p<0.001). However, the 
incidence of CRC was significantly greater in the LLS families than in sporadic CRC 
families (SIR in sporadic CRC: 0.48, 95% CI 0.27-0.79; p<0.001). The SIR for non-
colorectal LSRC was non-significantly higher in LS families (SIR 2.81, 95% CI 1.03-
6.12) compared to LLS families (SIR 1.69, 95% CI 0.73-3.34; p=0.09). There were no 
differences in SIR for non-colorectal LSRC between LLS families and sporadic 
CRC families (SIR 1.20, 95% CI 0.79-1.74; p=0.5). Taken together, the results indicate 
that, for CRC and non-colorectal LSRC, the highest risk is for LS families (SIR 4.69; 
95% CI 3.00-6.98), followed by LLS families (SIR 1.94; 95% CI 1.22-2.94; p<0.001). 
The risk in LLS families was significantly higher than the risk in relatives of patients with 
sporadic CRC (SIR 0.78; 95% CI 0.56-1.05; p<0.001).  
Figure 1 shows the cumulative age-of-onset curves for CRC among all relatives in the 
LS, LLS, and sporadic CRC groups. The relatives of patients with LLS developed CRC 
at an earlier mean age (53.71±16.8 years) than those with sporadic CRC (68.8±9 
years; p=0.004), but was similar to the mean age in LS patients (48.5±14.13; p=0.23). 
After a median 8.3 years of prospective follow-up, cancer pedigrees were updated in 
93 families: 10 in the LS group, 16 in the LLS group, and 67 in the sporadic CRC. A 
total of 533 first-degree relatives were included (including the index case): 41 from LS 
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families, 89 from LLS families, and 403 from sporadic CRC families. During this period, 
7 (17.1%) new cases of CRC or non-colorectal LSRC appeared in LS families, 4 (4.5%) 
new cases in LLS families, and 4 (1.0%) in families with sporadic CRC (Table 4). 
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DISCUSSION 
The main finding of our study is that the risk of CRC is lower in LLS families than 
among patients with genetically confirmed LS but significantly higher than in cases of 
sporadic CRC. The results confirm the need for a special surveillance strategy for these 
patients and their relatives. In addition, the age of onset for CRC in LLS families was 
similar to that of LS families. Differences between LLS families and families with 
sporadic CRC cases were more prominent in regards to CRC risk than for the risk of 
other LSRCs.  
Recent studies have shown that MSI testing and IHC analysis of MMR genes in 
all patients with CRC improves the detection of patients with LS.10, 17, 18 Because of the 
generalization of this universal strategy following Jerusalem guidelines,19 an increasing 
number of patients exhibit a loss of MMR protein expression with no pathogenic 
mutation. In CRC cases with a loss of MSH2, MSH6, PMS2, or MLH1 without 
hypermethylation, no cause of MMR gene inactivation is known other than germline 
mutation. In these cases, when a germline mutation is not found, a high suspicion of LS 
persists, and these patients and their relatives should be followed-up appropriately. The 
clinical characteristics of some of these patients suggest that they are clear hereditary 
cases, even though we were not able to find a genetic defect. Some of the pedigrees of 
patients with LLS showed a significant history of CRC with metachronous and 
synchronous tumors and fulfillment of the Amsterdam criteria. In these cases, the 
genetic defect was not found, probably due to it being located in a still unknown part of 
the gene, or simply that our technical capacity is not yet able to detect the pathogenic 
mutation. Some of these cases have been explained in the literature by alterations in 
other genes, such as in cases of EPCAM deletions or MLH1 constitutional 
epimutations. Other mechanisms, including inversions and duplications, could also 
explain some of these cases.20-26 However, some cases do not show any specific 
characteristics that suggest a hereditary origin. A notable proportion of LLS families do 
 17 
not have a history of other cancers, and the only reason to suspect LS is the presence 
of MSI and loss of MMR protein expression. In these cases, determining the 
appropriate counseling for patients and their relatives is difficult. It is possible that 
some of these LLS patients could be cases with CRC who may have false 
positive results of IHC and/or MSI or sporadic MMR-deficient CRC, and LLS 
patients would be a mixture of true LS patients with non-detected germline 
mutation and sporadic CRC cases. However, the high risk of CRC found in our study 
suggests that, in its entirety, LLS cases should be considered as high-risk cases and 
strategies for cancer prevention must be implemented in this group of patients and their 
relatives. The SIR of CRC for LLS families was similar to that described in a group of 
families with familial colorectal cancer syndrome type X, but in this syndrome no 
molecular alteration has been found.27 Even though LLS is a completely different entity 
because of the presence of MSI, the similar risk of CRC cancer should guarantee at 
least a similar surveillance program, even in cases without previous family history. Our 
results can contribute some rationale for designing follow-up strategies and, together 
with family history, can help clinicians appropriately schedule surveillance for these 
patients and their relatives. In our study, the age of CRC onset was similar to that of 
LS, and therefore surveillance strategies should start at the same age as 
recommended for LS cases. On the other hand, the frequency of CRC screening 
should be individualized. Given that the risk of CRC is lower in LLS families than in LS 
families, longer surveillance intervals for LLS cases and relatives without a prominent 
family history of CRC may be recommended. We have not found higher risk for non-
colorectal LSRC in LLS families compared to sporadic CRC families. However, 
that can be due to the small number of cases detected in our series. For this 
reason, specific recommendations for endometrial and other non-colorectal 
LSRC cannot be appropriately supported by our data.  
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The limitations of our study are the possibility of underreporting or misreporting cancers 
because our information was not always confirmed with objective clinical and 
pathological data. However, we think this limitation is minor because it would affect the 
LLS group to the same extent as the other groups. Another limitation is the relatively 
small number of families, especially in the prospectively followed cases, which 
precludes finding clear differences between groups. Moreover, the follow-up time for 
these cases could be considered too short. 
The main strength of our study is its population-based approach with cases ascertained 
from general clinics and not from specialized high-risk clinics. This approach provides 
robustness to our data in terms of potential applicability to general practice. Cancer risk 
can be overestimated in studies coming from select populations in genetic high-risk 
clinics. Studies based on recruitment through cancer genetics clinics do not usually 
correct for the selection bias caused by the over-representation of families with multiple 
cases in the data set.28, 29 Our results attempt to provide a rationale for follow-up and 
surveillance of this growing group of patients that will mostly be seen in the general 
clinics and not in high-risk clinics. New research is necessary to refine the classification 
of these patients in order to distinguish between sporadic and true hereditary cases. 
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Figure 1. Cumulative age of onset of colorectal cancer in first-degree relatives of Lynch 
syndrome, Lynch-like syndrome, and sporadic CRC. 
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Table 1. Demographic, clinical, and pathology data comparing LLS, LS, and 
sporadic CRC. 
  
LS  
(n=16) 
LLS  
(n=43) 
Sporadic CRC  
(n=1630) 
• Sex, % women (n) 62.5% (10) 55.8% (24)¶ 40.1% (654) 
• Median age, years 
(interquartile range) 
69 [51-75]  66 [55-73] ¶  71 [64-78]  
• Revised Bethesda Guidelines, 
% fulfillment (n) 
81.3% (13) 51.2% (22)§¶ 22.0% (358) 
• Location, % right colon (n) 56.3% (9) 55.8% (24)¶ 26.9% (438) 
• TNM Stage II, % (n)  50.0% (8)  59.0% (25)¶  39.6% (645) 
• Histology, % (n) 
• Poor differentiation 
• Lymphocytic infiltration 
• Mucinous 
 
25.0% (4)   
25.0% (4) 
20.0% (3) 
 
4.9% (2)§  
28.6% (12) 
36.6% (15)¶ 
 
8.3% (135)  
29.2% (475) 
13.0% (212) 
• Metachronous CRC, % (n) 12.5% (2) 0% (0) 1.2% (20) 
• Personal history of non-
colorectal LS cancer, % (n) 
43.8% (7) 11.6% (5)§¶ 3.3% (54) 
• Synchronous CRC, % (n) 12.5% (2) 9.3% (4) 5.6% (91) 
 
§ p < 0.05 LS patients vs LLS patients. 
¶ p < 0.05 LLS patients vs sporadic CRC patients. 
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Table 2. Characteristics and family history of LLS patients. 
Patient Protein lost Age  
index 
case 
No 
relatives 
with CRC § 
(n=14) 
No relatives 
with LSRC ŷ 
(n=8) 
Total of 
first-
degree 
relatives 
(n=177) 
% of 
CRC ‡ 
% of 
LSRC * 
1 PMS2 71 0 1 (pancreas) 10 0 10 
2 MLH1/PMS2 81 0 0 9 0 0 
3 MLH1/PMS2 73 0 0 7 0 0 
4 MLH1/PMS2 75 1  1 (stomach) 7 14.2 14.2 
5 MLH1/PMS2 45 3  1 (ovary) 10 30 10 
6 MSH2/MSH6 38 0 0 5 0 0 
7 MSH2/MSH6 74 0 0 6 0 0 
8 MSH2/MSH6 32 2 0 3 66.6 0 
9 MLH1/PMS2 72 2 3 (uterus) 11 18.1 27.2 
10 MLH1/PMS2 51 0 0 4 0 0 
11 MLH1/PMS2 46 1 1 (pancreas) 3 33.3 33.3 
12 MSH2/MSH6 69 1 0 9 11.1 0 
13 MSH6 55 0 0 6 0 0 
14 MSH6 56 0 0 4 0 0 
15 MLH1/PMS2 72 1 0 7 14.2 0 
16 MSH2/MSH6 69 0 0 5 0 0 
17 MSH2/MSH6 66 0 1 (stomach) 6 0 16.6 
18 MSH2/MSH6 66 0 0 9 0 0 
19 MLH1/PMS2 63 1 0 8 12.5 0 
20 MLH1/PMS2 46 0 0 11 0 0 
21 MLH1/PMS2 71 0 0 4 0 0 
22 MLH1/PMS2 69 1 0 12 8.3 0 
23 MLH1/PMS2 59 0 0 4 0 0 
24 MSH6 79 1 0 8 12.5 0 
25 MSH6 54 0 0 9 0 0 
 25 
 
 
§ Number of first-degree relatives diagnosed with CRC at any time until diagnosis of 
the index case. 
ŷ Number of first-degree relatives diagnosed with LSRC at any time until diagnosis of 
the index case. 
‡ Percentage of family members diagnosed with CRC at any time until diagnosis of the 
index case. 
* Percentage of family members diagnosed with LSRC at any time until diagnosis of 
the index case. 
NA: Not available 
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Table 3. Standardized incidence ratios between LLS families and LS/sporadic 
CRC families.  
 LS (n=80) 
  
LLS (n=177) 
  
Sporadic CRC (n=845) 
 No 
tumors 
SIR (95%CI) P-value 
§  
No tumors SIR (95%CI) P-value 
‡ 
No 
tumors 
SIR (95%CI) 
CRC 18 
 
6.04  
(3.58-9.54) 
<0.001 14 
 
2.12  
(1.16-3.56) 
<0.001 15 
 
0.48  
(0.27-0.79) 
No CRC 
LSRC  
6 
 
2.81 
(1.03-6.12) 
0.09 8 
 
1.69 
(0.73-3.34) 
0.5 27 
 
1.20 
(0.79-1.74) 
Total 24 
 
4.69  
(3.00-6.98) 
<0.001 22 
 
1.94  
(1.22-2.94) 
<0.001 42 
 
0.78 
(0.56-1.05) 
 
§ comparing the SIR of the LS and LLS groups. 
‡ comparing the SIR of the LLS and sporadic groups. 
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Table 4. Differences in the prospective appearance of new cancer cases between 
LLS families and LS/sporadic CRC families during follow-up.  
 
LS (n=41) P-value § LLS (n=89) P-value ‡ Sporadic CRC 
(n=403) 
CRC (%) 3 (7.3%) 0.16 2 (2.2%) 0.2 3 (0.7%) 
No CRC 
LSRC (%) 
4 (9.8%) 0.05 2 (2.2%) 0.02 1 (0.2%) 
Total 
cancers (%) 
7 (17.1%) 0.01  4 (4.5%) 0.01 4 (0.9%) 
 
§: comparing percentage of LS and LLS groups.  
‡: comparing percentage of LLS and sporadic groups. 
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Supplementary Table 1. Variants of uncertain significance. 
 
 
?  variant of uncertain clinical significance 
-? Likely not pathogenic 
 
 
 
 
 
Patient Sex Age MSI-h MMR 
protein loss 
Gene VUS  
(DNA 
change) 
Protein 
change 
Reported 
insight 
(times) 
Mainly 
reported 
as 
1 Female 80 No MLH1/PMS2 MLH1 c.1013 A>G p.Asn338Ser 14 -? (10/14) 
2 Female 80 Yes MLH1/PMS2 MLH1 c.1959 G>T p.Leu653Leu 20 ? (11/20) 
MLH1 c.1331 A>G p.Asn444Ser Not 
reported 
 
3 Female 72 Yes MLH1/PMS2 
MLH1 c.2401 G>A p.Ala681Thr 71 ? (43/71) 
4 Female 83 Yes MSH2/MSH6 MSH2 c.1021 C>G p.Leu341Val Not 
reported 
 
5 Male 66 Yes MSH2/MSH6 MSH2 c.366 +6 
T>C 
 
Not 
reported 
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ANNEX. Study participants: Members of the EPICOLON Consortium 
(Gastrointestinal Oncology Group of the Spanish Gastroenterological Association). 
Hospital 12 de Octubre, Madrid: Juan Diego Morillas (local coordinator), Raquel 
Muñoz, Marisa Manzano, Francisco Colina, Jose Díaz, Carolina Ibarrola, Guadalupe 
López, Alberto Ibáñez; Hospital Clínic, Barcelona: Antoni Castells (local coordinator), 
Virgínia Piñol, Sergi Castellví-Bel, Francesc Balaguer, Victoria Gonzalo, Teresa 
Ocaña, María Dolores Giráldez, Maria Pellisé, Anna Serradesanferm, Leticia Moreira, 
Miriam Cuatrecasas, Josep M. Piqué; Hospital Clínico Universitario, Zaragoza: Ángel 
Lanas (local coordinator), Javier Alcedo, Javier Ortego; Hospital Cristal-Piñor, 
Complexo Hospitalario de Ourense: Joaquin Cubiella (local coordinator), Mª Soledad 
Díez, Mercedes Salgado, Eloy Sánchez, Mariano Vega; Hospital del Mar, Barcelona: 
Montserrat Andreu (local coordinator), Anna Abuli, Xavier Bessa, Mar Iglesias, Agustín 
Seoane, Felipe Bory, Gemma Navarro, Beatriz Bellosillo; Josep Mª Dedeu, Cristina 
Álvarez, Begoña Gonzalez; Hospital San Eloy, Baracaldo and Hospital Donostia, 
CIBERehd, University of Country Basque, San Sebastián: Luis Bujanda (local 
coordinator) Ángel Cosme, Inés Gil, Mikel Larzabal, Carlos Placer, María del Mar 
Ramírez, Elisabeth Hijona, Jose M. Enríquez-Navascués y Jose L. Elosegui; Hospital 
General Universitario de Alicante: Artemio payá (EPICOLON I local coordinator), 
Rodrigo Jover (EPICOLON II local coordinator), Cristina Alenda, Laura Sempere, Nuria 
Acame, Estefanía Rojas, Lucía Pérez-Carbonell; Hospital General de Granollers: 
Joaquim Rigau (local coordinator), Ángel Serrano, Anna Giménez; Hospital General de 
Vic: Joan Saló (local coordinator), Eduard Batiste-Alentorn, Josefina Autonell, Ramon 
Barniol; Hospital General Universitario de Guadalajara and Fundación para la 
Formación e Investigación Sanitarias Murcia: Ana María García (local coordinator), 
Fernando Carballo, Antonio Bienvenido, Eduardo Sanz, Fernando González, Jaime 
Sánchez, Akiko Ono; Hospital General Universitario de Valencia: Mercedes Latorre 
(local coordinator), Enrique Medina, Jaime Cuquerella, Pilar Canelles, Miguel Martorell, 
José Ángel García, Francisco Quiles, Elisa Orti; CHUVI-Hospital Meixoeiro, Vigo: 
EPICOLON I: Juan Clofent (local coordinator), Jaime Seoane, Antoni Tardío, Eugenia 
Sanchez. EPICOLON II Mª Luisa de Castro (local coordinator), Antoni Tardío, Juan 
Clofent, Vicent Hernández; Hospital Universitari Germans Trias i Pujol, Badalona and 
Section of Digestive Diseases and Nutrition, University of Illinois at Chicago, IL, USA. : 
Xavier Llor (local coordinator), Rosa M. Xicola, Marta Piñol, Mercè Rosinach, Anna 
Roca, Elisenda Pons, José M. Hernández, Miquel A. Gassull; Hospital Universitari 
Mútua de Terrassa: Fernando Fernández-Bañares (local coordinator), Josep M. Viver, 
Antonio Salas, Jorge Espinós, Montserrat Forné, Maria Esteve; Hospital Universitari 
Arnau de Vilanova, Lleida: Josep M. Reñé (local coordinator), Carmen Piñol, Juan 
Buenestado, Joan Viñas; Hospital Universitario de Canarias: Enrique Quintero (local 
coordinator), David Nicolás, Adolfo Parra, Antonio Martín; Hospital Universitario La Fe, 
Valencia: Lidia Argüello (local coordinator), Vicente Pons, Virginia Pertejo, Teresa 
Sala; Hospital Sant Pau, Barcelona: Dolors Gonzalez (local coordinator) Eva Roman, 
Teresa Ramon, Maria Poca, Mª Mar Concepción, Marta Martin, Lourdes Pétriz; 
Hospital Xeral Cies, Vigo: Daniel Martinez (local coordinator); Fundacion Publica 
Galega de Medicina Xenomica (FPGMX), CIBERER, Genomic Medicine Group-
University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain: Ángel 
Carracedo (local coordinator), Clara Ruiz-Ponte, Ceres Fernández-Rozadilla, Mª 
Magdalena Castro; Hospital Universitario Central de Asturias: Sabino Riestra (local 
coordinator), Luis Rodrigo; Hospital de Galdácano, Vizcaya: Javier Fernández (local 
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coordinator), Jose Luis Cabriada; Fundación Hospital de Calahorra (La Rioja) La Rioja: 
Luis Carreño (local coordinator), Susana Oquiñena, Federico Bolado; Hospital Royo 
Villanova, Zaragoza: Elena Peña (local coordinator), José Manuel Blas, Gloria Ceña, 
Juan José Sebastián; Hospital Universitario Reina Sofía, Córdoba: Antonio Naranjo 
(local coordinator). 
 
 
 
 
